

INSULIN MEDIATED LIPOHYPERTROPHY

ABSTRACT:

Insulin is used to treat diabetes Type I and II. This article explains how a lipohypertrophy is caused by the insulin and explains the precautions that should be taken during the administration of insulin. Lipohypertrophy (LH) is a typical side effect of insulin therapy in subcutaneous tissue. Several injections at the same place result in this problem. A potential underlying mechanism of lipohypertrophy is the production of insulin antibodies. Recognizing and effectively managing these problems are crucial. In order to detect mild forms of lipohypertrophy, every patient should have their lips thoroughly evaluated for the condition during a diabetes clinic evaluation. The best current preventative and therapeutic approaches for lipohypertrophy are non-reuse of needles and rotation of injection sites with each injection. Education for both doctors and patients on recognising and treating lipohypertrophy is advisable.

KEYWORDS:

Diabetes, Insulin, Lipohypertrophy.

INTRODUCTION:

Cells can take up glucose, a sugar, from the blood thanks to the chemical messenger insulin. By promoting cellular glucose absorption and regulating carbohydrate, lipid, and protein metabolism, insulin, a peptide hormone released by the pancreatic islets of Langerhans cells, maintains appropriate blood glucose levels. It has 51 amino acids and is actually a dipeptide made up of A and B chains. When there is insufficient production or elevated insulin demands in the body, medical treatment with insulin is advised.[1]

Insulin is classified as rapid acting, short-acting, intermediate-acting, and long-acting depending on how long it takes to take effect.

1. Lispro and Aspart are examples of rapid-acting insulins that begin working within 5 to 15 minutes.
2. Regular insulin, which is short-acting, begins to work in 30 to 40 minutes.
3. The activity of intermediate-acting insulins (NPH) begins within one to four hours.
4. Long-acting insulins, such as glargine and detemir, begin to work within an hour or two.[2]

The main condition that insulin is used to treat is diabetes mellitus. In Type 1 or juvenile diabetes mellitus, the body's immune system or trauma or injury to the pancreas destroy pancreatic beta cells, which results in diminished or nonexistent insulin production. In those with type 1 diabetes, insulin is always necessary.[3] Type 2 diabetes mellitus is the most common type of diabetes and usually occurs after the age of 45 years. The exact cause of this is unknown, but factors such as genetic, obesity, metabolic syndrome, or sedentary lifestyle play a role. As the pancreas secretes more insulin to try to get glucose into the cells, they eventually burn out, and glucose starts building up in the blood. Treatment with insulin is necessary for the later stages of type 2 diabetes. [5,6]

Adverse effects of insulin classify according to those caused by the drug itself and those caused by the specific route of administration. Hypoglycemia is, by far, the most common adverse effect of insulin therapy.[4] Hyperglycemia symptoms include frequency urge to urinate, excessive thirst, unusual hunger, headaches, weight loss, dizziness, trouble speaking, confusion, pale skin sweating, seizure, loss of consciousness. [5,6] The other adverse effects of insulin therapy include weight gain and rarely electrolyte disturbances like hypokalemia, especially when used along with other drugs causing hypokalemia. The subcutaneous route of administration also has adverse effects. Pain at the injection site, lipodystrophy at the injection site are the most common adverse effects of daily subcutaneous injections.[7]

In diabetic patients, lipohypertrophy (LH) is a typical side effect of insulin therapy in subcutaneous tissue. On the skin's surface, it appears as soft, benign nodules [8]. Insulin's lipogenic effect at the injection site and repetitive stress from administering insulin at the same location are linked to the development of LH. The local inflammatory response, increased local

fibrosis, and decreased vascularity are likely to blame for the poor insulin absorption from the afflicted areas [9,10].

Several injections at the same place result in this problem. Patients frequently repeat injections in the same region since it is less painful than switching to a new unpleasant site. Type 1 diabetes, which requires longer-term insulin therapy, a large number of insulin injections, the reuse of needles (with a considerable increase if used more than five times), and the use of pen devices are other potential risk factors. A potential underlying mechanism is the production of insulin antibodies. [11,12]

Recognizing and effectively managing these problems are crucial. A medical professional should check injection sites at least once a year for any signs of lipohypertrophy or lipoatrophy. People should be told to refrain from injecting into lipohypertrophic areas until the aberrant tissue has returned to normal. The best current preventative and therapeutic approaches for lipohypertrophy are non-reuse of needles and rotation of injection sites with each injection. [13] It has been demonstrated that switching to humanised rapid-acting insulin will lessen this adverse effect since adipocytes are only briefly in contact with the insulin, minimising any local lipogenic effects.[14] If more cautious measures are unsuccessful, liposuction is a good fallback. Even though these lesions may spontaneously regress, it has been discovered to be advantageous to administer insulin injections coupled with tiny doses of dexamethasone. [15]

DISCUSSION:

Skin-related side effects from insulin therapy include lipoatrophy, lipohypertrophy, edoema, and allergies.[16] Patients who utilised porcine or bovine insulin experienced lipoatrophy, which is the loss of subcutaneous fat at the site of insulin injection. Due to the use of highly purified recombinant human insulin, this problem is now uncommon. The most frequent cutaneous complication, known as lipohypertrophy, is characterised by a tumor-like swelling of the adipose tissue near the sites of subcutaneous insulin injection. According to various studies, the prevalence of Type 1 diabetes ranges from 27 to 49%, and that of Type 2 diabetes is 4%. (17,18,19,20,21)

The type 1 diabetes in children and young adults administered the insulin at the same site which lead to lipohypertrophy and lipoatrophy which sometimes lead to decreased blood glucose levels and major complications like retinopathy and motor neuropathy. The Type 2 diabetes in an elder women administering insulin at the similar site caused bilateral lipohypertrophy.(22,23,24,25,26)

Due to the convenience of these locations for injection and the fact that the patient's hands naturally reach these areas, lipohypertrophy usually arises on both sides of the umbilicus or in the mid-thigh regions.(27) Sites are frequently asymmetrical because the dominant hand preferentially injects one side. The patient eventually experiences less discomfort while injecting the same location as the area becomes hyposensitive, which results in irregular insulin absorption

and poor glycaemic management. (26,28,29,30) It is generally accepted that the pathophysiology of insulin-induced lipohypertrophy is caused by the lipogenic effects of insulin, which cause adipocytes to grow and hypertrophy as a result of the stimulation of preadipocyte proliferation and differentiation. (26)

The incidence and prevalence of diabetes are rising alarmingly, and as a result of the oral hypoglycaemic drugs' failure to control blood sugar, the focus of treatment has shifted to using insulin, even though this has also led to novel complications. A total of 38% of patients in the United Kingdom Prospective Diabetes Study (UKPDS), whose participants were followed for more than ten years, needed insulin to bring their fasting plasma glucose levels down to 6 mmol/L. (31)

Patients who did not use larger injection sites, regularly rotate their insulin injection sites, administer conventional premixed insulins, and were underweight are more likely to experience lipohypertrophy. Further, needle reuse and frequent injections (basal-bolus regimen) did not increase the likelihood of lipohypertrophy. (32)

CONCLUSION:

Despite technological advancements, insulin-induced lipohypertrophy continues to be a prevalent but underappreciated cause of poor glycaemic control today, in the past, and in the future. In order to detect mild forms of lipohypertrophy, every patient should have their lips thoroughly evaluated for the condition during a diabetes clinic evaluation. If local insulin injection is carefully avoided, lipohypertrophies are frequently reversible. They can also be avoided by adhering to proper injection technique with systematic site variation. The most important and modifiable factors for reducing insulin-related lipohypertrophy in patients with type 1 diabetes are rotation of injections across a vast area and usage of rapid plus long-acting insulin analogues. Education for both doctors and patients on recognising and treating with lipohypertrophy is advisable.

REFERENCES:

1. Cefalu WT. Insulin resistance: cellular and clinical concepts. *Experimental biology and medicine*. 2001 Jan;226(1):13-26.
2. Pérez A,Ramos A,Carreras G, Insulin Therapy in Hospitalized Patients. *American journal of therapeutics*. 2020 Jan/Feb;
3. Smith MJ, Simmons KM, Cambier JC. B cells in type 1 diabetes mellitus and diabetic kidney disease. *Nature Reviews Nephrology*. 2017 Nov;13(11):712-20.
4. Unger J,Parkin C, Hypoglycemia in insulin-treated diabetes: a case for increased vigilance. *Postgraduate medicine*. 2011 Jul;
5. Donner T,Muñoz M, Update on insulin therapy for type 2 diabetes. *The Journal of clinical endocrinology and metabolism*. 2012 May;
6. Howard-Thompson A,Khan M,Jones M,George CM, Type 2 Diabetes Mellitus: Outpatient Insulin Management. *American family physician*. 2018 Jan 1;
7. Radermecker RP,Piérard GE,Scheen AJ, Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs. *American journal of clinical dermatology*. 2007;
8. T. Richardson and D. Kerr, "Skin-related complications of insulin therapy," *American Journal of Clinical Dermatology*, vol. 4, no. 10, pp. 661–667, 2003.
9. F. Bertuzzi, E. Meneghini, E. Bruschi, L. Luzi, M. Nichelatti, and O. Epis, "Ultrasound characterization of insulin induced lipohypertrophy in type 1 diabetes mellitus," *Journal of Endocrinological Investigation*, vol. 40, no. 10, pp. 1107–1113, 2017.
10. K. Raile, V. Noelle, R. Landgraf, and H. Schwarz, "Insulin antibodies are associated with lipoatrophy but also with lipohypertrophy in children and adolescents with type 1 diabetes," *Experimental and Clinical Endocrinology & Diabetes*, vol. 109, no. 08, pp. 393–396, 2001.
11. Reeves WG, Allen BR, Tattersall RB. Insulin-induced lipoatrophy: evidence for an immunopathogenesis. *BMJ*1980;**280**:1500-03.
12. Raile K, Noelle V, Landgraf R, *et al*. Insulin antibodies are associated with lipoatrophy but also with lipohypertrophy in children and adolescents with type 1 diabetes. *Exp Clin Endocrinol Diabetes* 2001;**109**:393-6.
13. Frid A, Hirsch L, Gaspar R, *et al*. New injection recommendations for patients with diabetes. *Diabetes Metab*2010;**36** Suppl 2:S3-18.
14. Roper NA, Bilous RW. Resolution of lipohypertrophy following change of short-acting insulin to insulin lispro (Humalog). *Diabet Med* 1998;**15**:1063-4.

15. Kumar O, Miller L, Mehtalia S. Use of dexamethasone in treatment of insulin lipoatrophy. *Diabetes* 1977;**26**:296-9.
16. Richardson T, Kerr D. Skin related complications of insulin therapy: Epidemiology and emerging management strategies. *Am J Clin Dermatol* 2003;4:661-7.
17. McNally PG, Jowett NI, Kurinczuk JJ, Peck RW, Hearnshaw JR. Lipohypertrophy and lipoatrophy complicating treatment with highly purified bovine and porcine insulin's. *Postgrad Med J* 1988;64:850-3.
18. Kordonouri O, Lauterborn R, Deiss D. Lipohypertrophy in young patients with type 1 diabetes. *Diabetes Care* 2002;25:634.
19. Vardar B, Kizilci S. Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. *Diabetes Res Clin Pract* 2007;77:231-6
20. Schiazza L, Occella C, Bleidl D, Rampini E. Insulin lipohypertrophy *J Am Acad Dermatol* 1990;22:148-9.
21. Hauner H, Stockhamp B, Haastert B. Prevalence of lipohypertrophy in insulin treated patients and predisposing factors. *Exp Clin Endocrinol Diabetes* 1996;104:106-10.
22. .Concurrence of Lipoatrophy and Lipohypertrophy in Children with Type 1 Diabetes Using Recombinant Human Insulin Arijit Singha; Rana Bhattacharjee; Sujoy Ghosh; Sumit Kumar Chakrabarti; Arjun Baidya; Subhankar Chowdhury2016;34(1):51–53
23. Dar IH, Dar SH, Wani S. Insulin lipohypertrophy: A non-fatal dermatological complication of diabetes mellitus reflecting poor glycemic control. *Saudi Journal of Medicine and Medical Sciences*. 2013 Jul 1;1(2):106.
24. Sharma D. A case of regression of insulin lipohypertrophy with correct injection technique. *Journal of Diabetology*. 2022 Apr 1;13(2):184.
25. Barola A, Tiwari P, Bhansali A. Insulin-mediated lipohypertrophy: an uncommon cause of diabetic ketoacidosis. *Case Reports*. 2017 Aug 11;2017:bcr-2017.
26. Fujikura J, Fujimoto M, Yasue S, Noguchi M, Masuzaki H, Hosoda K, Tachibana T, Sugihara H, Nakao K. Insulin-induced lipohypertrophy: report of a case with histopathology. *Endocrine journal*. 2005;52(5):623-8.
27. Chowdhury TA, Escudier V. Poor glycaemic control caused by insulin induced lipohypertrophy. *Bmj*. 2003 Aug 14;327(7411):383-4.
28. De Villiers FP. Lipohypertrophy—a complication of insulin injections. *Journal of Endocrinology, Metabolism and Diabetes of South Africa*. 2006 Nov 1;11(2):64-6.
29. Raile K, Noelle V, Landgraf R, Schwarz HP. Insulin antibodies are associated with lipoatrophy but also with lipohypertrophy in children and adolescents with type 1 diabetes. *Exp Clin Endocrinol Diabetes* 2001;109:393-6
30. Young RJ, Hannan WI, Frier BM, Steel JM, Duncan JP. Diabetic lipohypertrophy delays insulin absorption. *Diabetes Care* 1984;7:479-80.
31. UK Prospective Diabetes Study {UKPDS} Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998;352:837-53
32. Barola A, Tiwari P, Bhansali A, Grover S, Dayal D. Insulin-related lipohypertrophy: lipogenic action or tissue trauma?. *Frontiers in Endocrinology*. 2018 Oct 30;9:638.

